Thymic carcinoma in a 2-year-old child: case description and literature review

Thymic carcinoma (TC) belongs to a group of rare thymic epithelial tumours (TETs) arising from the anterior mediastinum. One of the most relevant established prognostic factors is complete surgical resection. Given the high invasive potential of TC a lot of patents at the diagnosis present with a locally advanced or metastatic disease, therefore complete resection could not be achieved, and a role of systemic therapy is increasing. Due to the rarity of this tumor type in children and adolescents, treatment approaches based on the guidelines for management of TETs in adults. In this article we report a case of TC in a 2-year-old boy. The literature review describes the current histological classification of the TET, approaches for systemic chemotherapy and local control in patients with TC.

1. Engels E.A. Epidemiology of thymoma and associated malignancies. J Thorac Oncol 2010;5(10 suppl 4):260–5. doi: 10.1097/JTO.0b013e3181f1f62d.

2. Ruffini E., Detterbeck F., Van Raemdonck D., Rocco G., Thomas P., Weder W., Brunelli A., Guererra F., Keshavjee S., Altorki N., Schutznerr J., Arame A., Spaggiari L., Lim E., Toker A., Venuta F. Thymic carcinoma: a cohort study of patients from the European Society of Thoracic Surgeons database. J Thorac Oncol 2014;9(4):541–8. doi: 10.1097/JTO.0000000000000128.

3. Stachowicz-Stencel T., Orbach D., Brecht I., Schneider D., Bien E., Synakiewicz A., Rod J., Ferrari A., Cecchetto G., Bisogno G. Thymoma and Thymic Carcinoma in Children and Adolescents: A Report from the European Cooperative Study Group for Pediatric Rare Tumors (EXPeRT). Eur J Cancer 2015;51(16):2444–52. doi: 10.1016/j.ejca.2015.06.121.

4. Sekihara K., Okuma Y., Kawamoto H., Hosomi Y. Clinical Outcome of Thymic Lymphoepithelioma-like Carcinoma: Case Report of a 14-Year-Old Male. Oncol Lett 2014;8(5):2183–6. doi: 10.3892/ol.2014.2475.

5. Girard N., Ruffini E., Marx A., Faivre-Finn C., Peters S. Thymic Epithelial Tumours: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann Oncol 2015;26 Suppl 5:40–55. doi: 10.1093/annonc/mdv277.

6. Travis W., Brambilla E., Burke A., Marx A., Nicholson A. WHO classification of tumours of the lung, pleura, thymus and heart. IARC Press, 2015.

7. Rosai J., Sobin L. Histological Typing of Tumours of the Thymus. Springer, Berlin, Heidelberg, 1999.

8. Kojima Y., Ito H., Hasegawa S., Sasaki T., Inui K. Resected invasive thymoma with multiple endocrine neoplasia type 1. Jpn J Thorac Caridovasc Surg 2006;54(4):171–3. doi: 10.1007/BF02662474.

9. Hsueh C., Kue T., Tsang N., Wu Y., Yang C., Hung I. Thymic Lymphoepitheliomalike Carcinoma in Children: Clinicopathologic Features and Molecular Analysis. J Pediatr Hematol Oncol 2006;28(12):785–90. doi: 10.1097/MPH.0b013e31802d3a83.

10. Evoli A., Lancaster E. Paraneoplastic disorders in thymoma patients. J Thorac Oncol 2014;9(9):143–7. doi: 10.1097/JTO.0000000000000300.

11. Chen G., Marx A., Wen-Hu C., Yong J., Puppe B., Stroebel P., MuellerHermlink H. New WHO histologic classifıcation predicts prognosis of thymic epithelial tumors: a clinicopathologic study of 200 thymoma cases from China. Cancer 2002;95(2):420–9. doi: 10.1002/cncr.10665.

12. Kondo K., Monden Y. Therapy for Thymic Epithelial Tumors: A Clinical Study of 1,320 Patients from Japan. Ann Thorac Surg 2003;76(3):878–84. https://doi.org/10.1016/S0003-4975(03)00555-1.

13. Stachowicz-Stencel T., Bien E., Balcerska A., Godzinski J., Synakiewicz A., Madziara W., Perek-Polnik M., Peregud-Pogorzelski J., Pietras W., Pobudejska A., Kurylak A., Mankowski P. Thymic carcinoma in children: a report from the Polish Pediatric Rare Tumors Study. Pediatr Blood Cancer 2010;54(7):916–20. doi: 10.1002/pbc.22482.

14. Carretto E., Inserra A., Ferrari A., Conte M., Di Cataldo A., Migliorati R., Cecchetto G., Bisogno G. Epithelial thymic tumours in paediatric age: a report from the TREP project. Orphanet J Rare Dis 2011;5(21):6–28. doi: 10.1186/1750-1172-6-28.

15. Litvak A., Woo K., Hayes S., Huang J., Rimner A., Sima C., Moreira A., Tsukazan M., Riely G. Clinical Characteristics and Outcomes for Patients With Thymic Carcinoma: Evaluation of Masaoka Staging. J Thorac Oncol 2014;9(12):1810–5. doi: 10.1097/JTO.0000000000000363.

16. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Thymomas and Thymic Carcinomas 2.2019. 2019 Mar 11. National Comprehensive Cancer Network. Abstract available at https://www.nccn.org/professionals/physician_gls/pdf/thymic.pdf.

17. Lemma G., Lee J., Aisner S., Langer C., Tester W., Johnson D., Loehrer P. Phase II Study of Carboplatin and Paclitaxel in Advanced Thymoma and Thymic Carcinoma. J Clin Oncol 2011;29(15):2060–5. doi: 10.1200/JCO.2010.32.9607.

18. Hirai F., Yamanaka T., Taguchi T., Daga H., Ono A., Tanaka K., Kogure Y., Shimizu J., Kimura T., Fukuoka J., Iwamoto Y., Sasaki H., Takeda K., Seto T., Ichinose Y., Nakagawa K., Nakanishi Y. A Multicenter Phase II Study of Carboplatin and Paclitaxel for Advanced Thymic Carcinoma: WJOG4207L. Ann Oncol 2015;26(2):363–8. doi: 10.1093/annonc/mdu541.

19. Petrini I., Zucali P., Lee H., Pineda M., Meltzer P., Walter-Rodriguez B., Roncalli M., Santoro A., Wang Y, Giaccone G. Expression and mutational status of c-Kit in thymic epithelial tumors. J Thorac Oncol 2010;5(9):1447–53 doi: 10.1097/JTO.0b013e3181e96e30.

20. Thomas A., Rajan A., Berman A., Tomita Y., Brzezniak C., Lee M., Lee S., Ling A., Spittler A., Carter C., Guha U., Wang Y., Szabo E., Meltzer P., Steinberg S., Trepel J., Loehrer P., Giaccone G. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma: an open-label phase 2 trial. Lancet Oncol 2015;16(2):177–86. doi:10.1016/S1470-2045(14)71181-7.

21. Giaccone G., Kim C., Thompson J., McGuire C., Kallakury B., Chahine J., Manning M., Mogg R., Blumenschein W., Tan M., Subramaniam D., Liu S., Kaplan I., McCutcheon J. Articles Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. Lancet Oncol 2018;19(3):347–55. doi: 10.1016/S1470-2045(18)30062-7.